Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGKA | P23743 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | RECQL | P46063 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | PRKCA | P17252 | 6/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | PAM | P19021 | 2/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | MGLL | Q99685 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3459097 | 0.96 | DGKA (0.56) | DGKAKMT2ASMN1; SMN2DNM1MAPK1 | |
| SCHEMBL3109452 | 0.94 | DGKA (0.58) | DGKAKMT2ASMN1; SMN2DNM1MAPT | |
| SCHEMBL3459572 | 0.92 | DGKA (0.51) | DGKAKMT2ASMN1; SMN2DNM1MAPK1 | |
| SCHEMBL3109237 | 0.91 | DGKA (0.40) | DGKAKMT2ASMN1; SMN2MAPK1MAPT | |
| SCHEMBL8264298 | 0.91 | DGKA (0.54) | DGKAKMT2ASMN1; SMN2DNM1MAPT | |
| SCHEMBL4696895 | 0.88 | DGKA (0.38) | DGKAKMT2ASMN1; SMN2MAPK1MAPT | |
| SCHEMBL4698358 | 0.88 | PRKCA (0.39) | DGKAMAPK1MAPTRECQLALDH1A1 | |
| SCHEMBL20810343 | 0.88 | ADRA2A (0.34) | DGKAMAPT | |
| SCHEMBL13541624 | 0.86 | ALDH1A1 (0.42) | KMT2ASMN1; SMN2MAPK1RECQLALDH1A1 | |
| SCHEMBL4700272 | 0.85 | BRD4 (0.42) | DGKAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7799829-B2 | Acyloxyalkyl carbamate prodrugs of α-amino acids, methods of synthesis and use | XENOPORT, INC. (US) | 2010-09-21 | — | — | US | disclosed |
| US-20090192225-A1 | Acyloxyalkyl Carbamate Prodrugs of Alpha-Amino Acids, Methods of Synthesis and Use | XENOPORT, INC. (US) | 2009-07-30 | — | — | US | disclosed |
| US-7531572-B2 | Acyloxyalkyl carbamate prodrugs of α-amino acids, methods of synthesis and use | XENOPORT, INC. (US) | 2009-05-12 | — | — | US | disclosed |
| EP-1919859-A2 | ACYLOXYALKYL CARBAMATE PRODRUGS OF TRANEXAMIC ACID, METHODS OF SYNTHESIS AND USE | Xenoport, Inc. (US) | 2008-05-14 | — | — | EP | disclosed |
| US-20080051458-A1 | Acyloxyalkyl carbamate prodrugs of alpha-amino acids, methods of synthesis and use | XENOPORT, INC. | 2008-02-28 | — | — | US | disclosed |
| WO-2008013860-A2 | ACYLOXYALKYL CARBAMATE PRODRUGS OF ALPHA-AMINO ACIDS, METHODS OF SYNTHESIS AND USE | XENOPORT, INC. (US) | 2008-01-31 | — | — | WO | disclosed |
| WO-2007002013-A2 | ACYLOXYALKYL CARBAMATE PRODRUGS OF TRANEXAMIC ACID, METHODS OF SYNTHESIS AND USE | XENOPORT, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192225-A1 | Acyloxyalkyl Carbamate Prodrugs of Alpha-Amino Acids, Methods of Synthesis and Use | ASNS, ASPH, DNPEP | DGKA 968/4885KMT2A 1398/4885SMN1; SMN2 2848/4885 |
| US-20080051458-A1 | Acyloxyalkyl carbamate prodrugs of alpha-amino acids, methods of synthesis and use | ASNS, ASPH, DNPEP | DGKA 968/4885KMT2A 1398/4885SMN1; SMN2 2848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.